India · Delayed Price · Currency is INR Jubilant Pharmova Statistics
Total Valuation
NSE:JUBLPHARMA has a market cap or net worth of INR 150.79 billion. The enterprise value is 174.28 billion.
| Market Cap | 150.79B |
| Enterprise Value | 174.28B |
Important Dates
The last earnings date was Friday, May 22, 2026.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
| Current Share Class | 158.40M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 7.67% |
| Owned by Institutions (%) | 23.39% |
| Float | 63.36M |
Valuation Ratios
The trailing PE ratio is 37.84 and the forward PE ratio is 25.14.
| PE Ratio | 37.84 |
| Forward PE | 25.14 |
| PS Ratio | 1.82 |
| PB Ratio | 2.13 |
| P/TBV Ratio | 5.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 12.29 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of -78.40.
| EV / Earnings | 43.74 |
| EV / Sales | 2.10 |
| EV / EBITDA | 13.84 |
| EV / EBIT | 21.28 |
| EV / FCF | -78.40 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.62 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 2.87 |
| Debt / FCF | -16.26 |
| Interest Coverage | 3.87 |
Financial Efficiency
Return on equity (ROE) is 5.96% and return on invested capital (ROIC) is 5.81%.
| Return on Equity (ROE) | 5.96% |
| Return on Assets (ROA) | 3.62% |
| Return on Invested Capital (ROIC) | 5.81% |
| Return on Capital Employed (ROCE) | 6.31% |
| Weighted Average Cost of Capital (WACC) | 6.42% |
| Revenue Per Employee | 14.93M |
| Profits Per Employee | 718,406 |
| Employee Count | 5,547 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.22 |
Taxes
In the past 12 months, NSE:JUBLPHARMA has paid 2.17 billion in taxes.
| Income Tax | 2.17B |
| Effective Tax Rate | 35.27% |
Stock Price Statistics
The stock price has decreased by -17.02% in the last 52 weeks. The beta is 0.51, so NSE:JUBLPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -17.02% |
| 50-Day Moving Average | 937.60 |
| 200-Day Moving Average | 1,009.61 |
| Relative Strength Index (RSI) | 40.05 |
| Average Volume (20 Days) | 141,712 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JUBLPHARMA had revenue of INR 82.80 billion and earned 3.99 billion in profits. Earnings per share was 25.08.
| Revenue | 82.80B |
| Gross Profit | 56.35B |
| Operating Income | 8.19B |
| Pretax Income | 6.14B |
| Net Income | 3.99B |
| EBITDA | 12.60B |
| EBIT | 8.19B |
| Earnings Per Share (EPS) | 25.08 |
Balance Sheet
The company has 12.68 billion in cash and 36.15 billion in debt, with a net cash position of -23.47 billion.
| Cash & Cash Equivalents | 12.68B |
| Total Debt | 36.15B |
| Net Cash | -23.47B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 70.96B |
| Book Value Per Share | 448.50 |
| Working Capital | 15.70B |
Cash Flow
In the last 12 months, operating cash flow was 12.27 billion and capital expenditures -14.49 billion, giving a free cash flow of -2.22 billion.
| Operating Cash Flow | 12.27B |
| Capital Expenditures | -14.49B |
| Depreciation & Amortization | 4.40B |
| Net Borrowing | 4.31B |
| Free Cash Flow | -2.22B |
| FCF Per Share | n/a |
Margins
Gross margin is 68.06%, with operating and profit margins of 9.90% and 4.81%.
| Gross Margin | 68.06% |
| Operating Margin | 9.90% |
| Pretax Margin | 7.42% |
| Profit Margin | 4.81% |
| EBITDA Margin | 15.22% |
| EBIT Margin | 9.90% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.51%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 0.51% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 19.95% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 0.50% |
| Earnings Yield | 2.64% |
| FCF Yield | -1.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:JUBLPHARMA is 1,244.00, which is 31.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1,244.00 |
| Price Target Difference | 31.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Mar 17, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |